{"id":"dacomitinib-pf-00299804","safety":{"commonSideEffects":[{"rate":"60–80","effect":"Diarrhea"},{"rate":"50–70","effect":"Rash/dermatitis"},{"rate":"30–50","effect":"Nausea"},{"rate":"20–40","effect":"Vomiting"},{"rate":"20–40","effect":"Fatigue"},{"rate":"15–30","effect":"Stomatitis"},{"rate":"15–25","effect":"Decreased appetite"}]},"_chembl":{"chemblId":"CHEMBL2110732","moleculeType":"Small molecule","molecularWeight":"469.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dacomitinib covalently binds to and inhibits multiple members of the human epidermal growth factor receptor (HER) family, particularly EGFR, HER2, and HER4. By blocking these receptor tyrosine kinases, it prevents downstream signaling pathways that drive cell proliferation and survival in HER-dependent cancers. This pan-HER inhibition provides broader coverage than first-generation EGFR inhibitors.","oneSentence":"Dacomitinib is a pan-HER tyrosine kinase inhibitor that irreversibly blocks EGFR, HER2, and HER4 signaling to inhibit tumor cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:30.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC) with EGFR mutations"},{"name":"First-line treatment of metastatic NSCLC with EGFR-activating mutations"}]},"trialDetails":[{"nctId":"NCT04721106","phase":"","title":"Korea Post Marketing Surveillance (PMS) Study of Vizimpro","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-03-07","conditions":"Lung Neoplasms","enrollment":188},{"nctId":"NCT03810807","phase":"PHASE1","title":"Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-01-17","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":22},{"nctId":"NCT07267247","phase":"","title":"Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2022-06-01","conditions":"Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), Drug-Related Side Effects and Adverse Reactions (MeSH Term), Egfr Tyrosine Kinase Inhibitor","enrollment":100},{"nctId":"NCT04504071","phase":"PHASE2","title":"Dacomitinib in Lung Cancer With Uncommon EGFR Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2020-12-08","conditions":"Non-small Cell Lung Cancer Metastatic, EGF-R Positive Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06321510","phase":"","title":"A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-07-01","conditions":"Lung Cancer","enrollment":29},{"nctId":"NCT02039336","phase":"PHASE1, PHASE2","title":"Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2014-04-02","conditions":"Colorectal Cancer","enrollment":35},{"nctId":"NCT04027647","phase":"PHASE2","title":"Phase 2 Study of Dacomitinib in NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2019-09-11","conditions":"NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV","enrollment":118},{"nctId":"NCT04946968","phase":"PHASE2","title":"Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2021-08-24","conditions":"Advanced Solid Tumours, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT04609319","phase":"","title":"Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-06-11","conditions":"Lung Cancer","enrollment":307},{"nctId":"NCT04155541","phase":"","title":"Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-01-24","conditions":"EGFR Mutation-positive Inoperable or Reccrent NSCLC","enrollment":40},{"nctId":"NCT03755102","phase":"EARLY_PHASE1","title":"A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-21","conditions":"EGFR Gene Mutation, Lung Cancer, Lung Cancer Metastatic","enrollment":17},{"nctId":"NCT05834348","phase":"","title":"A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-23","conditions":"Non-Small Cell Lung Cancer","enrollment":5279},{"nctId":"NCT04423185","phase":"PHASE2","title":"PLATFORM Study of Precision Medicine for Rare Tumors","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-08-15","conditions":"Rare Tumor","enrollment":770},{"nctId":"NCT06075615","phase":"","title":"A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2024-09-30","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":""},{"nctId":"NCT06486142","phase":"PHASE3","title":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study","status":"RECRUITING","sponsor":"Region Skane","startDate":"2022-09-21","conditions":"Non-Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT00728390","phase":"PHASE1","title":"A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-12-15","conditions":"Carcinoma, Non-Small Cell, Neoplasm Metastasis","enrollment":74},{"nctId":"NCT04511533","phase":"PHASE4","title":"Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-08-27","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":101},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT04397432","phase":"","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tian Xie","startDate":"2020-08-28","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":878},{"nctId":"NCT01774721","phase":"PHASE3","title":"ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-05-09","conditions":"Non-small Cell Lung Cancer With EGFR-Activating Mutations","enrollment":452},{"nctId":"NCT01000025","phase":"PHASE3","title":"PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2009-12-23","conditions":"Lung Cancer","enrollment":720},{"nctId":"NCT05271916","phase":"PHASE1, PHASE2","title":"First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2022-10-13","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":140},{"nctId":"NCT04811001","phase":"PHASE2","title":"Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations","status":"UNKNOWN","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2020-06-12","conditions":"NSCLC","enrollment":170},{"nctId":"NCT01920061","phase":"PHASE1","title":"A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-09-10","conditions":"Neoplasm","enrollment":110},{"nctId":"NCT01520870","phase":"PHASE2","title":"Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Neurooncología","startDate":"2012-02","conditions":"Glioblastoma, Brain Tumor, Recurrent","enrollment":49},{"nctId":"NCT01728233","phase":"PHASE2","title":"Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2013-06-15","conditions":"Penile Neoplasms, Carcinoma, Squamous Cell","enrollment":32},{"nctId":"NCT04768491","phase":"","title":"Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC","status":"UNKNOWN","sponsor":"Peking Union Medical College","startDate":"2020-09-01","conditions":"EGFR Activating Mutation, NSCLC Stage IV, NSCLC Stage IIIB","enrollment":82},{"nctId":"NCT00768664","phase":"PHASE2","title":"Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11-04","conditions":"Head and Neck Neoplasms","enrollment":69},{"nctId":"NCT04675008","phase":"PHASE2","title":"Central Nervous System(CNS) Efficacy of Dacomitinib","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2020-12-07","conditions":"Non Small Cell Lung Cancer, Brain Metastases","enrollment":30},{"nctId":"NCT03865446","phase":"PHASE1","title":"Evaluate Severe Hepatic Impairment on Dacomitinib PK","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-04-05","conditions":"Severe Hepatic Impairment","enrollment":16},{"nctId":"NCT04575415","phase":"","title":"Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2020-10-07","conditions":"NSCLC","enrollment":272},{"nctId":"NCT00553254","phase":"PHASE2","title":"Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-02-05","conditions":"Carcinoma, Non Small Cell Lung","enrollment":55},{"nctId":"NCT02382796","phase":"PHASE2","title":"A Rollover Protocol of Dacomitinib For Patients In Japan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-07-10","conditions":"NSCLC","enrollment":7},{"nctId":"NCT04339829","phase":"PHASE2","title":"An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2020-08-01","conditions":"Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases","enrollment":50},{"nctId":"NCT01918761","phase":"PHASE1","title":"Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Central European Cooperative Oncology Group","startDate":"2013-07-30","conditions":"Non Small Cell Lung Cancer","enrollment":5},{"nctId":"NCT01441128","phase":"PHASE1","title":"-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-01","conditions":"Carcinoma, Non-Small Cell Lung, Adenocarcinoma, Carcinoma, Squamous Cell","enrollment":20},{"nctId":"NCT00548093","phase":"PHASE2","title":"PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-04-29","conditions":"Carcinoma, Non Small Cell Lung","enrollment":66},{"nctId":"NCT01465802","phase":"PHASE2","title":"Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-12-26","conditions":"Non Small Cell Lung Cancer (NSCLC)","enrollment":236},{"nctId":"NCT00818441","phase":"PHASE2","title":"Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-03-11","conditions":"Carcinoma, Non-small Cell","enrollment":119},{"nctId":"NCT00225121","phase":"PHASE1","title":"Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-10-11","conditions":"Neoplasms","enrollment":121},{"nctId":"NCT01112527","phase":"PHASE2","title":"PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-04","conditions":"Glioblastoma, GBM, Glioblastoma Multiforme","enrollment":58},{"nctId":"NCT00728468","phase":"PHASE1","title":"A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Advanced Malignant Solid Tumors","enrollment":16},{"nctId":"NCT01858389","phase":"PHASE2","title":"A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07","conditions":"Non-small Cell Lung Cancer","enrollment":41},{"nctId":"NCT01360554","phase":"PHASE3","title":"ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-06-16","conditions":"Non-Small Cell Lung Cancer","enrollment":878},{"nctId":"NCT02047747","phase":"PHASE2","title":"A Phase II Study of Dacomitinib in Progressive Brain Metastases","status":"TERMINATED","sponsor":"David Piccioni, M.D., Ph.D","startDate":"2014-02","conditions":"Brain Cancer","enrollment":4},{"nctId":"NCT01608022","phase":"PHASE2","title":"A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-07","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":48},{"nctId":"NCT02268747","phase":"PHASE2","title":"Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2014-11","conditions":"Skin Squamous Cell Cancer","enrollment":43},{"nctId":"NCT01737008","phase":"PHASE1","title":"Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2013-01","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":12},{"nctId":"NCT01152853","phase":"PHASE2","title":"PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2010-07","conditions":"Advanced Gastric Cancer, HER2","enrollment":28},{"nctId":"NCT01121575","phase":"PHASE1","title":"A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Non Small Cell Lung Cancer","enrollment":70},{"nctId":"NCT01796327","phase":"PHASE1","title":"A Study To Assess Absorption Of Study Drug Dacomitinib (PF-00299804), Given As An Oral Tablet Compared To An Intravenous Infusion In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT00769067","phase":"PHASE2","title":"A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11","conditions":"Non-small Cell Lung Cancer","enrollment":188},{"nctId":"NCT01484847","phase":"NA","title":"A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2011-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":6},{"nctId":"NCT01116843","phase":"PHASE1, PHASE2","title":"Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2010-05","conditions":"Oral Cavity Cancer","enrollment":13},{"nctId":"NCT02097433","phase":"PHASE1","title":"Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-07","conditions":"Healthy","enrollment":14},{"nctId":"NCT01449201","phase":"PHASE2","title":"PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-10","conditions":"Head Neck Cancer Squamous Cell Metastatic, Head Neck Cancer Squamous Cell Recurrent","enrollment":49},{"nctId":"NCT01702506","phase":"PHASE1","title":"Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-10","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT01571388","phase":"PHASE1","title":"A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-04","conditions":"Healthy, Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction","enrollment":25},{"nctId":"NCT01318031","phase":"PHASE1","title":"Study To Investigate The Potential Drug Drug Interaction (DDI) Between PF-00299804 And Paroxetine In Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-03","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT00971191","phase":"PHASE1","title":"A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-02","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":22},{"nctId":"NCT01313793","phase":"PHASE1","title":"A Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-04","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT00783328","phase":"PHASE1","title":"A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11","conditions":"Neoplasms","enrollment":13},{"nctId":"NCT01034748","phase":"PHASE1","title":"A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":6},{"nctId":"NCT00999817","phase":"PHASE1","title":"A Pharmacokinetic (PK) Study Of PF-00299804 And Dextromethorphan In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-11","conditions":"Healthy Volunteers","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dacomitinib"],"phase":"phase_3","status":"active","brandName":"Dacomitinib (PF-00299804)","genericName":"Dacomitinib (PF-00299804)","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dacomitinib is a pan-HER tyrosine kinase inhibitor that irreversibly blocks EGFR, HER2, and HER4 signaling to inhibit tumor cell growth. Used for Non-small cell lung cancer (NSCLC) with EGFR mutations, First-line treatment of metastatic NSCLC with EGFR-activating mutations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}